Dermelix Collaborates with EspeRare to Co-develop and Commercialize DMX-101 for XLHED

 Dermelix Collaborates with EspeRare to Co-develop and Commercialize DMX-101 for XLHED

Dermelix Collaborates with EspeRare to Co-develop and Commercialize DMX-101 for XLHED

Shots:

  • EspeRare to get EU development rights of DMX-101, developed under the name ER-004. Dermelix to get WW development & exclusive commercialization rights for EspeRare’s DMX-101 (Ex- Europe)
  • In H2’19 Dermelix & EspeRare plans for the onset of clinical study assessing DMX-101 in 15 patients with X-linked hypohidrotic ectodermal dysplasia (XLHED) in the US and Europe
  •  EspeRare’s DMX-101 is an EDA molecule consisting of IgG1 Fc sequence linked with EDA TNF binds to the receptor EDAR resulting in activation of the NFϰB signaling pathway and has received EMA’s PRIME & FDA’s OD designation for XLHED 

Click here to read full press release/ article | Ref: EspeRare | Image: Behance

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post